title: The somatotropic axis in postmenopausal women during six month of transdermal continuous 17beta-estradiol administration combined with oral medroxyprogesterone.
abstract: OBJECTIVE
  The evaluation of the influence of continuous transdermal estradiol supplementation combined with oral medroxyprogesterone on the somatotropic axis in postmenopausal women.
  
  
  METHODS
  25 women completed the study Group A--13 women received transdermal 17beta-estradiol (Oesclim 50 - Fournier-Solvay) combined with oral 5 mg daily medroxyprogesterone (Gestomikron - Adamed). Group B--12 women without treatment. Basic plasma FSH, estradiol, glucose, insulin, SHBG, hGH, total and free IGF-I, IGFBP-1 as well as IGFBP-3 were measured initially and at the 12th and 24th week of the study.
  
  
  RESULTS
  The mean plasma FSH level was reduced and mean plasma estradiol level was increased in group A during estradiol supplementation. Mean plasma level of free IGF-I and free to total IGF-I ratio were increased in group A during 24 weeks of hormone therapy. In the control group (group B) there was the significant increase in mean plasma IGFBP-3 level. Other parameters showed no significant changes in the control group.
  
  
  CONCLUSIONS
  The administration of transdermal 17beta-estradiol combined with oral medroxyprogesterone increases the IGF-I bioavailability. However this influence do not exceed the physiologial level of IGF-I bioavailability.
authors: Klinika Endokrynologii Ginekologicznej, Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, Polska. milewicz@interia.eu
authors: Tomasz
authors: T
authors: Milewicz
authors: Józef
authors: J
authors: Krzysiek
authors: Iwona
authors: I
authors: Rogatko
authors: Krystyna
authors: K
authors: Sztefko
authors: Ewa
authors: E
authors: Stochmal
authors: Alicja
authors: A
authors: Hubalewska-Dydejczyk
authors: Robert
authors: R
authors: Jach
authors: Stanisław
authors: S
authors: Radowicki
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000187:drug effects*; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage*; D008875:Middle Aged; D011044:Poland; D017698:Postmenopause / Q000097:blood / Q000187:drug effects*; D016387:Women's Health
chemical_list: D004958:Estradiol; D013006:Growth Hormone; D008525:Medroxyprogesterone